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Cytomegalovirus (CMV) retinitis may be treated systemically or intravitreally. We reviewed
retrospectively patients with CMV retinitis, in order to determine whether systemic treatment was
associated with less spread of CMV retinitis from one eye to the other. Of 222 cases, 92 patients
had bilateral disease at onset of CMV retinitis, leaving 130 for analysis. Bilaterality occurred in 10
patients during 12,687 days of systemic treatment and in 34 during 14,791 days without systemic
treatment (odds ratio [OR] = 2.92; confidence interval [CI], 1.44-5.90). Patients who had received
systemic treatment for <50% of the follow-up period had a greater risk of bilaterality (OR = 3.7;
CI, 2.79-4.54) than did the more intensively treated patients. CD4 cell levels also contributed to
increased risk, but multivariate analysis showed that CD4 cell counts and treatment intensity were
independent risk factors. CMV retinitis was more likely to become bilateral in patients who received
less intravenous therapy. Local treatment can complete but does not replace systemically adminis-
tered therapy.
Cytomegalovirus (CMV) retinitis is the most common intra-
ocular infection in patients with AIDS, occurring in an esti-
mated 20% [1, 2]. Untreated, it destroys the retina and leads
to blindness. Two antiviral drugs are currently available for
treatment of CMV retinitis: ganciclovir (DHPG, dihydroxy-
propoxy-methyl-guanine) and foscarnet (trisodium phosphono-
formate). They both inhibit DNA replication of CMV; foscamet
also inhibits the reverse transcriptase of HIV.
Each drug can be administered intravenously and is given in
an initial high-dose induction course during 2-3 weeks, followed
by long-term, low-dose maintenance therapy. Foscarnet [3, 4]
and particularly ganciclovir can also be injected intravitreally,
or an intravitreal device releasing ganciclovir can be inserted [5,
6]. Oral ganciclovir is being introduced into clinical practice [7,
8]. New drugs and drug combinations are under investigation
[9]; of these, cidofovir has recently been licensed and can be
used both intravenously and intravitreally [10].
The most common adverse effect of intravenous ganciclovir
is bone marrow suppression, mostly as neutropenia and throm-
bocytopenia [11, 12]. Zidovudine must usually be withdrawn
during intravenous ganciclovir treatment because it also
causes neutropenia. Foscarnet is nephrotoxic and may lead to
hypocalcemia, hypokalemia, hypophosphatemia, and hypo-
magnesemia [12]. Avoidance of these side effects is a poten-
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tial advantage, but while intravitreal therapy is locally effica-
cious, it probably does not have systemic effects against CMV
infection [5, 6, 13].
Possibly, in patients with unilateral retinitis, the initially
uninvolved eye might be protected by systemic therapy but not
by intravitreal therapy. To test this hypothesis we reviewed
patients with unilateral retinitis to see if the initially uninvolved
eye might be protected by systemic but not intravitreal therapy.
Methods
Records of the Swiss HIV Cohort Study (SHCS) [14] indi-
cated which patients, among the more than 7,000 enrolled, had
had CMV retinitis diagnosed. Charts of all such patients with
CMV retinitis diagnosed by an ophthalmologist from 1985 to
July 1995 at three major university hospitals in Switzerland
(Universitatsspital Zurich, Centre Hospitalier Universitaire
Vaudois in Lausanne, and HOpital Cantonal Universitaire in
Geneva) were reviewed. CMV retinitis was defined by the
characteristic ophthalmoscopic picture of necrotizing retinitis
with or without hemorrhage.
We excluded all patients whose CMV retinitis was bilateral
when first detected. All patients with unilateral CMV retinitis
were followed until death or up to July 1995, whichever came
first. Patients were seen at least monthly by an ophthalmologist.
Date of birth, sex, risk factors for HIV infection, CD4 cell
counts, date of diagnosis of CMV retinitis in the first infected
eye (and, in cases of bilaterality, the date of diagnosis of that
in the second eye), and duration of systemic anti-CMV medica-
tions (ganciclovir and/or foscarnet), as well as survival data,
were obtained from the SHCS and from chart review.
Patients were treated with intravenous ganciclovir and/or
foscarnet and/or intravitreal ganciclovir, or they were not
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treated. Intravenous treatment consisted of an induction dosage
of 10 mg/(kg • d) of ganciclovir or 180 mg/(kg • d) of foscarnet,
followed by a maintenance dosage of 5 mg/(kg • d) of gan-
ciclovir, or 90-120 mg/(kg • d) of foscarnet, for 5-6 days out
of 7. Intravitreal ganciclovir was injected in a dose of 400 mg
twice or three times a week as induction therapy and then once
weekly for maintenance therapy.
For patients who developed bilateral disease, follow-up
started with the date of diagnosis of CMV retinitis in the first
affected eye and ended with the date of diagnosis of such
disease in the other eye; for those who did not, follow-up
ended on the date of the last examination. For each patient,
we determined the number of days on which systemic treatment
or no such treatment was given during follow-up. The definition
of "no treatment" included anything other than systemic ther-
apy with ganciclovir or foscarnet. The intensity of systemic
treatment was defined as the percentage of days of systemic
treatment.
The probability that the initially healthy eye would become
involved with CMV retinitis was analyzed according to the
Kaplan-Meier and Cox methods. Possible confounding factors
such as the CD4 cell count and the year of treatment were
examined by multivariate analysis. Foxpro (Fox Software, Per-
rysburg, OH), Epi-Info (Centers for Disease Control and Pre-
vention, Atlanta), and SPSS software (SPSS, Chicago) for the
Windows operating system (Microsoft, Seattle) were used.
Results
We found 222 first episodes of CMV retinitis recorded in
the SHCS database. Of these, 92 were bilateral at the time of
diagnosis, leaving 130 cases of initially unilateral retinitis in
the three centers for analysis (table 1). Treatment strategies
differed among the three centers. Whereas physicians in Zurich
insisted on intravenous administration, those in Lausanne had
an active interest in developing intravitreal therapy. Patients
in Zurich received intravenous treatment during 70% of
follow-up, compared with 23% in Geneva and 14% in Lau-
sanne. This difference between Zurich and Lausanne is signifi-
cant (P < .02 by log-rank test).
Patients with initially unilateral CMV retinitis were followed
for a total of 23,560 days. During 11,028 days patients were
receiving intravenous ganciclovir or foscarnet; 10 bilateralities
occurred during treatment, for an incidence of 0.91 per 1,000
days of follow-up. Similarly, 34 bilateralities occurred during
14,791 days without treatment, for an incidence of 2.71 per
1,000 days of follow-up without treatment. The relative risk
of bilaterality without treatment compared with that during
treatment was 2.97 (CI, 1.44-5.90).
In order to allow for carryover effects, the analysis was
repeated, and bilaterality occurring within the first 2 weeks
after treatment was started or stopped was assigned to the
preceding period. However, the results did not change. In a
second analysis, we divided patients into two groups, according
to whether they received intravenous treatment for more or less
than 50% of the follow-up days. The probability of bilaterality
was plotted according to the Kaplan-Meier method and is
shown in figure 1. The differences between the two treatment-
intensity groups were highly significant (table 2).
As expected, because treatment modalities depended so
highly on the center, an analogous analysis for the centers also
yielded significant differences. CD4 cell percentages seem to
influence the risk of bilaterality (table 2) as well. We therefore
performed a multivariate analysis (table 3), in which the treat-
ment effect (-_.50%/>50%) was adjusted for CD4 cell percent-
ages (<2%/>2%). This adjustment did not notably influence
relative risks and confidence intervals, a finding indicating that
the two risk factors are independent.
Discussion
The data we have collected shows a strong inverse associa-
tion between intravenous treatment and bilaterality of CMV
retinitis. In patients who received such treatment for >50% of
Table 1. Data regarding the 130 analyzed patients with initially unilateral CMV retinitis at three
centers in Switzerland.
Variable Total Zurich Geneva Lausanne
No. of patients 130 52 45 33
Mean age (y) 39 39 41 37
Males (%) 82 86 84 73
Homosexuals (%) 59 73 56 39
Drug addicts (%) 17 11.5 22 18
Heterosexuals and others* (%) 24 15.5 22 43
Occurrence of bilateralization 34 19 33 58
Mean follow-up (d) 211 280 164 168
Administration of iv ganciclovir or foscarnet
(percent of follow-up) 46 70 23 14
* Others includes those with undetermined risk factors (3), multiple risk factors (2), and blood transfusions (1).
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Figure 1. Incidence of bilaterality
as related to intensity of intravenous
treatment. The difference between
the two treatment-intensity groups is
statistically significant (P < .01 by
log-rank test).
Table 2. Risk factors for bilaterality of CMV retinitis.
No. of patients
Factor
With spread
to other eye
(n = 44)
Without spread
to other eye
(n = 86) OR (95% CI) P value
Sex
Male 36 71 1.00
Female 8 15 1.05 (0.37-2.96) .92
Age (y)*
.---.35 15 33 0.68 (0.26-1.80) .73
35.1-45 16 24 1.00
>45 13 29 0.67 (0.24-1.84) .73
Risk groups
Homosexuals 25 36 1.00
Heterosexuals and others 1 11 14 1.13 (0.40-3.20) .80
Drug addicts 4 18 0.32 (0.07-1.15) .06
Center
Zurich 10 42 1.00
Geneva 15 30 2.10 (0.76-5.89) .18
Lausanne 19 14 5.70 (1.94-17.15) .0007
CD4 cell percentage
High: >2% 14 47 1.00
Low: ..-_2% 26 32 2.73 (1.16-6.50) .02
Year of diagnosis II
<1991 16 33 1.00
1991-1992 13 25 1.07 (0.40-2.89) .89
>1992 15 28 1.10 (0.43-2.87) .82
Intensity of iv treatment
High: >50% 11 45 1.00
Low: --._.50% 33 41 3.29 (1.38-7.98) .003
* Reference age group: 35.1-45 years.
t Reference group: homosexuals.
Others includes those with undetermined risk factors (3), multiple risk factors (2), and blood transfusions (1).
Reference: Zurich.
it Reference: <1991.
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Table 3. Data regarding a multivariate analysis, in which treatment
effect was adjusted for CD4 cell percentages.
Factor
OR (CI) before
adjustment
OR (CI) after
adjustment
Intensity of treatment
High: >50% 1.00 1.00
Low: --50% 3.29 (1.38-7.98) 4.32 (3.40 -5.26)
CD4 cell percentage
High: >2% 1.00 1.00
Low: 2.73 (1.16-6.5) 2.79 (1.90-3.67)
Year of diagnosis
<1991 1.00 1.00
1991-1992 2.07 (0.40-2.49) 1.24 (0.16 -2.31)
>1992 1.10 (0.43-2.87) 1.67 (0.56-2.75)
the follow-up time, the median interval until bilaterality oc-
curred was 175 days; in those who received less intravenous
treatment, that interval amounted to only 99 days.
It is tempting to jump from association to causation and
conclude that retinitis became bilateral because intravenous
treatment was not intense enough. However, since this was
not a prospective, randomized trial, the possibility of con-
founding factors needs to be considered. Multivariate analy-
sis suggests that CD4 cell percentages were not responsible
for the association between treatment and involvement of
the initially healthy eye.
Antiretroviral therapy is another potential confounder. Ad-
ministration of azidothymidine in Switzerland began in 1988,
and that of zalcitabine and didanosine began in 1991; combina-
tion therapy became popular in 1993. Patients whose CMV
retinitis was diagnosed later received more antiretroviral treat-
ment. However, when stratification according to year of diag-
nosis was added to the multivariate analysis, this did not change
the relative risks associated with intensity of anti-CMV treat-
ment. These analyses reinforce the hypothesis of causal rela-
tion, although in the absence of randomization other unidenti-
fied confounders may exist.
Many of our patients who did not have intravenous therapy
received intravitreal injections of ganciclovir. Older studies [13,
15] enrolled few patients with unilateral retinitis [13] or used a
combination of intravitreal and intravenous ganciclovir in most
patients [15]; for that reason, they may have missed the risk of
bilaterality. However, in a larger trial of ganciclovir implants, a
high incidence of bilaterality was also observed [6, 16].
Our analysis did not cover side effects and visual outcome;
we did not think that retrospective chart review would yield
data of sufficient quality. Mortality data showed a trend fa-
voring more intensive intravenous therapy, but this may be due
to the fact that untreated patients were seen early in the AIDS
epidemic, when survival was poor. Therefore, we cannot claim
that more intensively treated patients did better overall.
Without results of a randomized, prospective trial, retro-
spective data appropriately guide clinical practice. These
data suggest that local therapy by injections or implants may
supplement but not replace systemic therapy. Because of the
toxicity and expense of intravenous therapy, this is a bitter
pill to swallow, sweetened perhaps by the availability of oral
ganciclovir.
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